322 related articles for article (PubMed ID: 33824342)
21. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection.
Ansari A; Arya R; Sachan S; Jha SN; Kalia A; Lall A; Sette A; Grifoni A; Weiskopf D; Coshic P; Sharma A; Gupta N
Front Immunol; 2021; 12():636768. PubMed ID: 33777028
[TBL] [Abstract][Full Text] [Related]
22. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.
Alrubayyi A; Gea-Mallorquí E; Touizer E; Hameiri-Bowen D; Kopycinski J; Charlton B; Fisher-Pearson N; Muir L; Rosa A; Roustan C; Earl C; Cherepanov P; Pellegrino P; Waters L; Burns F; Kinloch S; Dong T; Dorrell L; Rowland-Jones S; McCoy LE; Peppa D
Nat Commun; 2021 Oct; 12(1):5839. PubMed ID: 34611163
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors.
Shomuradova AS; Vagida MS; Sheetikov SA; Zornikova KV; Kiryukhin D; Titov A; Peshkova IO; Khmelevskaya A; Dianov DV; Malasheva M; Shmelev A; Serdyuk Y; Bagaev DV; Pivnyuk A; Shcherbinin DS; Maleeva AV; Shakirova NT; Pilunov A; Malko DB; Khamaganova EG; Biderman B; Ivanov A; Shugay M; Efimov GA
Immunity; 2020 Dec; 53(6):1245-1257.e5. PubMed ID: 33326767
[TBL] [Abstract][Full Text] [Related]
24. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Ewer KJ; Barrett JR; Belij-Rammerstorfer S; Sharpe H; Makinson R; Morter R; Flaxman A; Wright D; Bellamy D; Bittaye M; Dold C; Provine NM; Aboagye J; Fowler J; Silk SE; Alderson J; Aley PK; Angus B; Berrie E; Bibi S; Cicconi P; Clutterbuck EA; Chelysheva I; Folegatti PM; Fuskova M; Green CM; Jenkin D; Kerridge S; Lawrie A; Minassian AM; Moore M; Mujadidi Y; Plested E; Poulton I; Ramasamy MN; Robinson H; Song R; Snape MD; Tarrant R; Voysey M; Watson MEE; Douglas AD; Hill AVS; Gilbert SC; Pollard AJ; Lambe T;
Nat Med; 2021 Feb; 27(2):270-278. PubMed ID: 33335323
[TBL] [Abstract][Full Text] [Related]
25. Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.
Reche PA
Front Immunol; 2020; 11():586984. PubMed ID: 33178220
[TBL] [Abstract][Full Text] [Related]
26. Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals.
Quiros-Fernandez I; Poorebrahim M; Fakhr E; Cid-Arregui A
EBioMedicine; 2021 Oct; 72():103610. PubMed ID: 34627082
[TBL] [Abstract][Full Text] [Related]
27. Development of an in-house SARS-CoV-2 interferon-gamma ELISpot and plate reader-free spot detection method.
Mak WA; Koeleman JGM; Ong DSY
J Virol Methods; 2022 Feb; 300():114398. PubMed ID: 34863782
[TBL] [Abstract][Full Text] [Related]
28. Cross-Recognition of SARS-CoV-2 B-Cell Epitopes with Other Betacoronavirus Nucleoproteins.
Tajuelo A; López-Siles M; Más V; Pérez-Romero P; Aguado JM; Briz V; McConnell MJ; Martín-Galiano AJ; López D
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328398
[TBL] [Abstract][Full Text] [Related]
29. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients.
Yang LT; Peng H; Zhu ZL; Li G; Huang ZT; Zhao ZX; Koup RA; Bailer RT; Wu CY
Clin Immunol; 2006 Aug; 120(2):171-8. PubMed ID: 16781892
[TBL] [Abstract][Full Text] [Related]
30. Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG.
Schwarzkopf S; Krawczyk A; Knop D; Klump H; Heinold A; Heinemann FM; Thümmler L; Temme C; Breyer M; Witzke O; Dittmer U; Lenz V; Horn PA; Lindemann M
Emerg Infect Dis; 2021 Jan; 27(1):. PubMed ID: 33058753
[TBL] [Abstract][Full Text] [Related]
31. Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.
Zeng Q; Li YZ; Dong SY; Chen ZT; Gao XY; Zhang H; Huang G; Xu Y
Front Immunol; 2020; 11():596684. PubMed ID: 33362779
[TBL] [Abstract][Full Text] [Related]
32. SARS CoV-2 infections in healthcare workers with a pre-existing T-cell response: a prospective cohort study.
Casado JL; Häemmerle J; Vizcarra P; Velasco H; Velasco T; Fernandez-Escribano M; Vallejo A
Clin Microbiol Infect; 2021 Jun; 27(6):916.e1-916.e4. PubMed ID: 33667629
[TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells.
Jung JH; Rha MS; Sa M; Choi HK; Jeon JH; Seok H; Park DW; Park SH; Jeong HW; Choi WS; Shin EC
Nat Commun; 2021 Jun; 12(1):4043. PubMed ID: 34193870
[TBL] [Abstract][Full Text] [Related]
34. CD4
Taborska P; Strizova Z; Stakheev D; Sojka L; Bartunkova J; Smrz D
Front Immunol; 2021; 12():629102. PubMed ID: 34012431
[TBL] [Abstract][Full Text] [Related]
35. Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers.
Jackson-Thompson BM; Goguet E; Laing ED; Olsen CH; Pollett S; Hollis-Perry KM; Maiolatesi SE; Illinik L; Ramsey KF; Reyes AE; Alcorta Y; Wong MA; Davies J; Ortega O; Parmelee E; Lindrose AR; Moser M; Graydon E; Letizia AG; Duplessis CA; Ganesan A; Pratt KP; Malloy AM; Scott DW; Anderson SK; Snow AL; Dalgard CL; Powers JH; Tribble D; Burgess TH; Broder CC; Mitre E
BMC Infect Dis; 2021 Jun; 21(1):544. PubMed ID: 34107889
[TBL] [Abstract][Full Text] [Related]
36. Suboptimal SARS-CoV-2-specific CD8
Habel JR; Nguyen THO; van de Sandt CE; Juno JA; Chaurasia P; Wragg K; Koutsakos M; Hensen L; Jia X; Chua B; Zhang W; Tan HX; Flanagan KL; Doolan DL; Torresi J; Chen W; Wakim LM; Cheng AC; Doherty PC; Petersen J; Rossjohn J; Wheatley AK; Kent SJ; Rowntree LC; Kedzierska K
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24384-24391. PubMed ID: 32913053
[TBL] [Abstract][Full Text] [Related]
37. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection.
Song G; He WT; Callaghan S; Anzanello F; Huang D; Ricketts J; Torres JL; Beutler N; Peng L; Vargas S; Cassell J; Parren M; Yang L; Ignacio C; Smith DM; Voss JE; Nemazee D; Ward AB; Rogers T; Burton DR; Andrabi R
Nat Commun; 2021 May; 12(1):2938. PubMed ID: 34011939
[TBL] [Abstract][Full Text] [Related]
38. SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.
Schmidt KG; Nganou-Makamdop K; Tenbusch M; El Kenz B; Maier C; Lapuente D; Überla K; Spriewald B; Bergmann S; Harrer EG; Harrer T
Front Immunol; 2021; 12():627568. PubMed ID: 33995351
[TBL] [Abstract][Full Text] [Related]
39. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Grifoni A; Weiskopf D; Ramirez SI; Mateus J; Dan JM; Moderbacher CR; Rawlings SA; Sutherland A; Premkumar L; Jadi RS; Marrama D; de Silva AM; Frazier A; Carlin AF; Greenbaum JA; Peters B; Krammer F; Smith DM; Crotty S; Sette A
Cell; 2020 Jun; 181(7):1489-1501.e15. PubMed ID: 32473127
[TBL] [Abstract][Full Text] [Related]
40. Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses.
Jordan SC
Clin Exp Immunol; 2021 Jun; 204(3):310-320. PubMed ID: 33534923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
